Previous 10 | Next 10 |
Amarin Corporation plc (AMRN) Jefferies Virtual Healthcare Conference June 2, 2021 9:30 AM ET Company Participants John Thero – President and Chief Executive Officer Karim Mikhail – Senior Vice President, Commercial Head-Europe Conference Call Participants Michael Yee – J...
Amarin (NASDAQ: AMRN) rose to end Tuesday nearly 5.1% higher after the company provided details from clinical studies of the components of its one commercialized drug. In a presentation at the American College of Cardiology's Annual Scientific Session, Amarin presented findings ...
DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Karim Mikhail, Amarin’s senior vice president and head of commercial for Europe and fut...
REDUCE-IT ® patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C levels Patients randomized to VASCEPA in EVAPORATE trial, in analyses ...
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels Amarin to Webcast Discussion of Data Presented at AC...
Shares of Amarin (NASDAQ: AMRN) were tumbling 5.5% lower as of 10:40 a.m. EDT on Wednesday after falling as much as 7.2% earlier in the session. The decline came after Goldman Sachs downgraded the stock from a neutral rating to sell and slashed its price target from $5 per share to ...
Novavax cut to neutral at JP Morgan; manufacturing issues citedNovavax (NVAX) topped Street estimates with its Q1 2021 financials, but a delayed timeline outlined for its COVID-19 vaccine candidate hurt the stock yesterday leading to a ~14.4% slump.Today, J.P. Morgan has downgraded ...
DUBLIN, Ireland and BRIDGEWATER, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new clinical data and other research results regarding VASCEPA® (icosapent ethyl) and its unique active ingredient will be presented at ACC.21, the American...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Underlying the strong performance of small caps in the fi...
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q1 2021 Earnings Call Apr 29, 2021 , 7:30 a.m. ET Operator Continue reading For further details see: Amarin (AMRN) Q1 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...